Friends of the ATA
 

Education | Research | News | Donate

November 2010
>> If you are unable to read this message or view images please visit the online version.
> > Click here to forward this e-mail to a friend!

Friends of the ATA e-news!
Learn. Share. Give.
Keeping you up to date with the latest thyroid information!

Restrictions lifted on the marketing and distribution of Thyrogen® within the United States
Genzyme Corporation (Cambridge, MA), currently under a consent decree with the U.S. Food and Drug Administration (FDA) regarding manufacturing issues of several products reports that they have completed terms of the consent decree regarding Thyrogen® by notifying the FDA that they have transferred all of their Thyrogen® fill/finish operations for the US market out of their Allston facility and into the facility with Hospira, a third party company. As a result of this action, Genzyme is no longer required to include a letter of medical necessity with Thyrogen® shipments to distributors and is able to resume Thyrogen® product promotional activities. Genzyme reports that a limited and diminishing number of Allston completed Thyrogen® kits remain in the US market while much larger numbers of Hospira completed kits have already been shipped to distributors for use within the US market. Additional details are available at: http://www.businesswire.com/news/home/20101124005412/en/Genzyme-Successfully-Meets-Milestones-FDA-Consent-Decree

ATA Webinars: Education When and Where You Want It!
As awareness and the prevalence of thyroid disease and its related disorders grows so also arises the need for education of health care professionals and the general public. The American Thyroid Association (ATA) remains at the forefront of CME certified thyroid education. We invite you to join us in the launch of our newest educational initiative. ATA will be hosting a series webinars beginning December 14 and every third Tuesday of the month at 11:00 AM ET thereafter.

Clinical Thyroidology for Patients
Up- to-date information to help you understand thyroid disease through the latest research.

IN THE OCTOBER ISSUE, STUDIES ASK THE FOLLOWING QUESTIONS:

  • Are there other types of thyroid imaging studies that may be helpful in patients with thyroid cancer?
  • Do antibodies affect measurement of thyroglobulin levels in thyroid cancer patients?
  • Should we be concerned with transiently low thyroid hormone levels in preterm infants?
  • Is there a correlation between thyroid hormone levels and bone density in men?
  • Is there an association between thyroid hormone levels in the normal range and miscarriage?

We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.

— Alan P. Farwell, MD

Clinical Thyroidology for Patients October Volume 3 Issue 10

THYROID CANCER Pertechnetate thyroid scanning is a low-cost and widely available option for patients who require thyroid imaging before Radioactive Iodine therapy

THYROID CANCER Care should be taken in interpreting blood thyroglobulin levels in thyroid cancer

THYROID HORMONE AND PREGNANCY Transient hypothyroxinemia may affect brain development in preterm infants

 

THYROID AND BONE Thyroid Hormone Levels and Bone Density in Men

THYROID AND PREGNANCY TSH concentration is increased and FT4 is decreased in pregnancies resulting in miscarriage or fetal death


Your Support Generates Thyroid Education and Thyroid Awareness Around the World!

ATA Annual Fund


The ATA exists to serve the public and to improve patient care. Your contribution supports:

  • Physician referral access to top-notch, Endocrinologists from around the world
  • News publication with the latest clinical research: Clinical Thyroidology for Patients
  • ATA sponsored Clinical Management Guidelines available free online
  • The latest in Thyroid Health Education for patients and the public
  • Advocacy for Thyroid Drug Safety and Efficacy
  • Thyroidologists Dedicated to patients and patient care

Government employees: If you are a government employee, you can support thyroid research through the annual Combined Federal Campaign (CFC #12088), which runs September 1st - December 15th. Government employees include:

  • Federal
  • U.S. Military
  • U.S. Postal Service

Local, state, county, municipal and school board employees should check with their local campaign administrator to see if the American Thyroid Association is included. When selecting which organization to contribute to, please be sure to choose CFC #12088 to designate the American Thyroid Association.

With the philanthropic support of our members and friends, the ATA will continue to provide and cultivate these invaluable resources and programs for the ATA Community. Your donation is fully tax-deductible and directly supports efforts that ultimately improve thyroid patients' lives. So please, take a moment to Donate Today!

ATA Annual Fund

Thank you for your continued support!


American Thyroid Association
6066 Leesburg Pike
Suite 550
Falls Church, Virginia 22041
e-mail: thyroid@thyroid.org
web site: www.thyroid.org

This email was sent to you by the American Thyroid Association because you subscribed to our Friends of the ATA e-news mailing list. To ensure delivery to your inbox, please add ata@atafriends.thyroid.org to your address book or safe list.

Click here to modify your profile.

If you prefer not to receive these informational emails, you may click here or reply to this message and put UNSUBSCRIBE in the subject line.

  

Medical Disclaimer
The information contained in or made available through the American Thyroid Association Website is not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians. The user should consult a physician in all matters relating to his or her health, and particularly in respect to any symptoms that may require diagnosis or medical attention.

We respect your privacy. For more information, view our privacy policy.

PLEASE DO NOT REPLY TO THIS MESSAGE. For questions or comments, please contact thyroid@thyroid.org